<DOC>
	<DOCNO>NCT02972216</DOCNO>
	<brief_summary>A Post-marketing Surveillance Study Evaluate Effectiveness Safety Docetaxel-Based Chemotherapy</brief_summary>
	<brief_title>Post-marketing Surveillance Study Docetaxel-Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically confirm unresectable locally advanced NSCLC progress recur four previous docetaxelfree chemotherapy regimen , unresectable locally advanced metastatic SCCHN recur previous docetaxelfree chemotherapy regimens 1 . Women nurse pregnant study period ; 2 . Patients carcinoid tumor , smallcell carcinoma lung ; 3 . A history another malignancy within last five year ( except cure basal cell carcinoma skin cure carcinoma situ uterine cervix ) ; 4 . Any morbidity situation contraindication chemotherapy ( e.g . active infection , myocardial infarction precede 6 month ) ; 5 . Neutrophil count &lt; 1,500 cells/mm3 ; 6 . A history hypersensitivity docetaxel cisplatin ; 7 . Symptomatic heart disease include unstable angina , congestive heart failure uncontrolled arrhythmias ; 8 . Subjects active hepatitis ; 9 . Subjects know positive Human Immunodeficiency Virus ( HIV ) ; 10 . Any condition judge investigator , participate study jeopardize patient 's wellbeing</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>